PROFILE |
 |
Before the newest drugs hit the prescription pad, they first have to go through a long series of clinical trials to make sure they're safe and effective, and that's where ICON steps in. ICON provides the pharmaceutical and biotechnology industries in Europe, North America, and the Pacific Rim with clinical research services relating to these trials. With expertise in therapeutic areas ranging from oncology to neurology, ICON manages, executes, and analyzes multinational clinical trials, providing study design, data management and analysis, laboratory services, and regulatory-affairs consulting. Co-founders Ronan Lambe (chairman) and John Climax (CEO) each own about 24% of ICON's stock.
COMPETITION |
 |
Covance Inc. (CVD)
Pharmaceutical Product Development, Inc. (PPDI)
Quintiles Transnational Corp. (QTRN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: May
2001 Sales (mil.): 116.20
1-Yr. Sales Growth: 43.8%
Employees: 1,030
Revenue per employee: $112,815.53
KEY PEOPLE |
 |
John Climax
CEO
Peter Gray
CFO
CONTACT INFO |
 |
South County Business Park, Leopardstown
Dublin 18, Ireland
Phone: 353-1-2161-100
Fax: 353-1-2161-200
Online: Web Site
|